Through many years of involvement and achievements in the pharmaceutical industry, Skyepharma’s development and manufacturing facility is eminently specialized in classic and complex Oral Solid Dosage Forms.
20 years of experience in complex oral forms
Skyepharma was originally founded in 1983 as the creation of JAGO AG by Jacques Gonnella, a small Swiss private company specialized in development.
JAGO acquired the first Geomatrix patent from the University of Pavia, allowing the creation of its drug delivery business, soon validated by the approval in the USA of the first product based on Dilacor technology developed on behalf of RPR.
Ian Gowrie-Smith, founder of Medeva, created SkyePharma plc as a virtual entity. Using funds from the sale of Medeva, Skyepharma then acquired JAGO AG, trading under that brand before rebranding as Skyepharma AG two years later.
Skyepharma acquired its Saint-Quentin-Fallavier production site from Wyeth*. Skyepharma has subsequently invested in the site to adapt it to the production of modified-release tablets, particularly those using the patented Geomatrix technology.
The manufacture of these tablets began in the pilot plant in December 1998 for a US generic and led to FDA certification of the site. Skyepharma had developed an mdDPI Foradil (formoterol) for Novartis that had been approved in more than 30 countries including the USA. The Saint Quentin site ensured the filling of IPR until the product was withdrawn from the market.
Skyepharma developed its business by acquiring several companies: The American company Depotech (San Diego), specialized in the development of sustained-release injectables, which became « Skyepharma Inc ». Bioglan Pharma (DK) and Hyal Pharmaceutical (Canada) Corporation, both specialized in topical products -Hyal originated Solaraze- And, the Montreal-based RTP pharma company that was the origin of Triglide.
Skyepharma sold Skyepharma Inc (formerly Depotech), Bioglan, and closed Skyepharma Canada (formerly RTP) to refocus on its historical activities: oral and inhalation. Skyepharma Inc is now PACIRA.
Between 2011 and 2016, the Saint-Quentin-Fallavier site was under a management lease agreement with the German CMO Aenova. The owner was Skyepharma plc and the tenant was Aenova. The activity was carried out under the name Aenova.
In 2016, following the lease management by Aenova, SkyePharma PLC merged with the Vectura group, an industry-leading inhaled airways disease-focused business. The inhaled activity of SkyePharma PLC was absorbed by Vectura and Skyepharma Production was created as an entity to perform Oral Business Unit activities.
Skyepharma is now the oral business unit of the Vectura
Group of companies.
* The Saint-Quentin-Fallavier plant was built in 1990 by the American laboratory Lederle, then a subsidiary of the American Cyanamid chemical group (Lederle then became Wyeth-Lederle, a subsidiary of the American Home
Products group, which was itself acquired by Pfizer). The site replaced the
former Oullins (Rhône) plant.